{
    "id": 20483,
    "fullName": "ATM positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ATM positive indicates the presence of the ATM gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 472,
        "geneSymbol": "ATM",
        "terms": [
            "ATM",
            "AT1",
            "ATA",
            "ATC",
            "ATD",
            "ATDC",
            "ATE",
            "TEL1",
            "TELO1"
        ]
    },
    "variant": "positive",
    "createDate": "03/30/2016",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1390 inhibited Atm activity, sensitized glioblastoma cell lines to radiotherapy in culture, and demonstrated efficacy in mouse models of glioblastoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).",
            "molecularProfile": {
                "id": 20966,
                "profileName": "ATM positive"
            },
            "therapy": {
                "id": 7032,
                "therapyName": "AZD1390",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11499,
                    "pubMedId": null,
                    "title": "AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14189,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).",
            "molecularProfile": {
                "id": 20966,
                "profileName": "ATM positive"
            },
            "therapy": {
                "id": 7032,
                "therapyName": "AZD1390",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11499,
                    "pubMedId": null,
                    "title": "AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5525,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bladder cancer cells resistant to radiotherapy due to decreased Dab2ip expression and subsequent ATM over expression, were re-sensitized to radiotherapy by dKU-55933 treatment in culture (PMID: 25585815).",
            "molecularProfile": {
                "id": 20967,
                "profileName": "ATM pos DAB2IP dec exp"
            },
            "therapy": {
                "id": 3879,
                "therapyName": "KU-55933 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5086,
                    "pubMedId": 25585815,
                    "title": "The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25585815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20966,
            "profileName": "ATM positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20967,
            "profileName": "ATM pos DAB2IP dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}